Drugs / CM93
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04933422 | Jan 2027 → Jul 2029 expected | glioblastoma | Crimson Biopharm Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM93 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933422 ↗ |
| Action | Inhibit | “potent inhibitor of EGFR mutations” NCT04933422 ↗ |
| Modality | Small molecule | “small molecule” NCT04933422 ↗ |
| Route | Oral | “oral capsule of CM93 administered once daily” NCT04933422 ↗ |
| Target | EGFR | “potent inhibitor of EGFR mutations” NCT04933422 ↗ |